| Authors: |
Richard VR; Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada., Mitsa G; Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montréal, Quebec H4A 3J1, Canada., Eshghi A; University of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8, Canada., Chaplygina D; Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada., Mohammed Y; Center for Proteomics and Metabolomics, Leiden University Medical Center, Leiden 2333 ZC, The Netherlands., Goodlett DR; University of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8, Canada., Zahedi RP; Manitoba Centre for Proteomics and Systems Biology, Winnipeg, Manitoba R3E 3P4, Canada.; Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba R3E 3P4, Canada.; Department of Biochemistry and Medical Genetics, University of Manitoba, Winnipeg, Manitoba R3E 0J9, Canada.; CancerCare Manitoba Research Institute, Winnipeg, Manitoba R3E 0V9, Canada., Thevis M; Institute of Biochemistry, Center for Preventive Doping Research, German Sport University Cologne, Cologne 50933, Germany.; European Monitoring Center for Emerging Doping Agents (EuMoCEDA), Cologne/Bonn 50933, Germany., Borchers CH; Segal Cancer Proteomics Centre, Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Quebec H3T 1E2, Canada.; Division of Experimental Medicine, McGill University, Montréal, Quebec H4A 3J1, Canada.; Gerald Bronfman Department of Oncology, McGill University, Montréal, Quebec H4A 3T2, Canada.; Department of Pathology, McGill University, Montréal, Quebec H4A 3J1, Canada. |
